Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Atomoxetine · Atomoxetine Hydrochloride, Strattera

Small molecule · Inhibitor of norepinephrine transporter (SLC6A2) · developed by Lilly

Approved FDA, Nov 2002
1 Registered trials

What is Atomoxetine?

Atomoxetine is a selective norepinephrine reuptake inhibitor that acts by inhibiting the presynaptic norepinephrine transporter. It is also studied in obstructive sleep apnea.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Atomoxetine Hydrochloride, Strattera
Drug type
Small molecule
Targets
norepinephrine transporter (SLC6A2)
Mechanism
Inhibitor of norepinephrine transporter (SLC6A2)
Pathways
norepinephrine reuptake
Therapy area
Respiratory
Developer
Lilly
In trials of
APMD
FDA status
Approved as Atomoxetine Hydrochloride, Strattera (November 26, 2002), NDA021411 · FDA label
UNII
ASW034S0B8

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05101122 Phase 1/2 Obstructive Sleep Apnea Completed APMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obstructive Sleep Apnea

Other drugs acting on SLC6A2

Bupropion FDA approved Solriamfetol FDA approved CTx-1301-Dexmethylphenidate Phase 3 PDC-1421 Phase 2

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.